Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00587444 · ClinicalTrials.gov registry record · Phase 3

Optimal Heparin Dosing Regimens for Cardiopulmonary Bypass

A Phase 3 study of Postoperative Hemorrhage, sponsored by Mayo Clinic.

Completed
Registry status
Phase 3
Development phase
270
Enrollment target
1
Study location

NCT00587444: Completed Phase 3 study of Postoperative Hemorrhage, sponsored by Mayo Clinic.

NCT00587444 is a Phase 3 study of Postoperative Hemorrhage that has completed, run by Mayo Clinic. The registered enrollment target is 270 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00587444, a Phase 3 study of Postoperative Hemorrhage, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
Phase 3
Development phase
270 participants
Enrollment target
1
Study location

Study Summary

Study has been completed and is in the data analysis and manuscript writing phase of the project.

Conditions Studied

Interventions

  • DRUG Heparin
  • DRUG HH or high heparin
  • DRUG heparin concentration HC

Study Locations (1)

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 270 participants
Start Date 2001-06
Est. Completion 2007-10
Phase Phase 3
Mayo Clinic

2,844 total trials

What the finished NCT00587444 record still lists

NCT00587444 is an interventional study that assigns participants to a tested intervention. The registered 270 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (65% lower).

The record links to 1 condition, with Postoperative Hemorrhage appearing as the primary indexed condition, and to 3 interventions - of which Heparin is the first listed.

NCT00587444 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT00587444 about?

NCT00587444 is a clinical study titled "Optimal Heparin Dosing Regimens for Cardiopulmonary Bypass". Study has been completed and is in the data analysis and manuscript writing phase of the project.

What is the current status of trial NCT00587444?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 270 participants. The study started on 2001-06. Estimated completion is 2007-10.

What conditions does trial NCT00587444 study?

This clinical trial studies the following conditions: Postoperative Hemorrhage.

What interventions are being tested in trial NCT00587444?

The interventions under investigation include: Heparin (DRUG), HH or high heparin (DRUG), heparin concentration HC (DRUG).

Who is sponsoring clinical trial NCT00587444?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00587444 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

How this trial's enrollment target compares

Where NCT00587444's enrollment target sits among peer trials

270 1217th of 2000 higher than 781 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00801489 · 270 participants · Phase 2

    Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

  • NCT04372485 · 270 participants · NA

    Using Mobile Health (mHealth) to Improve STI Treatment Adherence Among Adolescents

  • NCT04528446 · 270 participants

    The Impact of Glomerular Disorders on Bone Quality and Strength

  • NCT05215327 · 270 participants · Phase 2

    High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00587444, the US trial registry maintained by the National Library of Medicine. NCT00587444 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.